Myosin5a tail associates directly with Rab3A-containing compartments in neurons by Wollert, Torsten et al.
1Myosin5a Tail Associates Directly With Rab3A-containing Compartments In Neurons
Torsten Wöllert1,2,3, Anamika Patel2, Ying-Lung Lee1, D. William Provance, Jr.4, Valarie E.
Vought2, Michael S. Cosgrove2, John A. Mercer4, and George M. Langford1,2,3,5
From the 1Department of Biological Sciences, Dartmouth College, Hanover, NH 03755, 2Department of
Biology, Syracuse University, Syracuse, NY 13244, the 3Marine Biological Laboratory, Woods Hole, MA
02543, and the 4McLaughlin Research Institute, Great Falls, MT 59405
Running title: Direct association of Myo5a tail with Rab3A
5 To whom correspondence should be addressed: Dept. of Biology, Syracuse University, 107 College
Place, Syracuse, NY 13244. Tel.: 315-443-3949; Fax: 315-443-5390; E-mail: glangfor@syr.edu
Myosin-Va (Myo5a) is a motor protein
associated with synaptic vesicles (SVs) but the
mechanism by which it interacts has not yet
been identified. A potential class of binding
partners are Rab GTPases and Rab3A is known
to associate with SVs and is involved in SV
trafficking. We performed experiments to
determine whether Rab3A interacts with
Myo5a and whether it is required for transport
of neuronal vesicles. In vitro motility assays
performed with axoplasm from the squid giant
axon showed a requirement for a Rab GTPase
in Myo5a-dependent vesicle transport.
Furthermore, mouse recombinant Myo5a tail
revealed that it associated with Rab3A in rat
brain synaptosomal preparations in vitro and
the association was confirmed by
immunofluorescence imaging of primary
neurons isolated from the frontal cortex of
mouse brains. Synaptosomal Rab3A was
retained on recombinant GST-tagged Myo5a
tail affinity columns in a GTP-dependent
manner. Finally, the direct interaction of
Myo5a and Rab3A was determined by
s e d i m e n t a t i o n  v e l o c i t y  a n a l y t i c a l
ultracentrifugation using recombinant mouse
Myo5a tail and human Rab3A. When both
proteins were incubated in the presence of 1
mM GTPγS, Myo5a tail and Rab3A formed a
complex and a direct interaction was observed.
Further analysis revealed that GTP-bound
Rab3A interacts with both the monomeric and
dimeric species of the Myo5a tail. However, the
interaction between Myo5a tail and nucleotide-
free Rab3A did not occur. Thus, our results
show that Myo5a and Rab3A are direct binding
partners and interact on SVs and that the
Myo5a/Rab3A complex is involved in transport
of neuronal vesicles.
INTRODUCTION
In presynaptic nerve terminals,
neurotransmitter molecules are stored in SVs and
are released by the fusion of these vesicles with the
plasma membrane. This process and the
positioning of SVs at the plasma membrane is
regulated by SV-associated proteins, including
synapsins, synaptotagmin, synaptobrevin,
synaptophysin, calmodulin-dependent kinase II
(CaMKII), SV2 and the GTPase Rab3A (1). The
mechanism by which actin-dependent motors
deliver SVs to the plasma membrane for fusion
and the proteins involved are not understood. In
this study, we investigated the interaction between
Myo5a and Rab3A, two known proteins on SVs.
Rab3A belongs to the Ras superfamily of
small monomeric GTPases that is implicated in
vesicle fusion and regulated secretion, particularly
in neurotransmitter release (2). Mammals have
four members of the Rab3 family: Rab3A, Rab3B,
Rab3C, and Rab3D, which are predominantly
expressed in the brain and neuroendocrine tissues
(3). Rab3A is localized to SVs in the active or
GTP-bound form and dissociates from the vesicle
upon GTP hydrolysis or depolarization of the
nerve terminal. The inactive or GDP-bound form
of Rab3A binds to Rab GDP dissociation inhibitor
(RabGDI). When GDP-GTP exchange occurs
Rab3A is able to associate with SVs again (4).
GTP-bound Rab3A interacts with multiple specific
effector proteins, notably Rabphilin3A (5), RIM
(6), Rabin3A (7), and synapsin 1 (8). In addition to
Rab3A, only Rabphilin3A and synapsin 1 are
known to be localized to SVs.
Myosin-Va (Myo5a) is an actin-based
molecular motor that is involved in many cellular
processes. As with all myosins, the head domain
binds to F-actin and hydrolyzes ATP, whereas the
tail domain functions in cargo transport and binds
to cargo-specific adaptor proteins or associate with
2lipid membranes (9). In vitro, the globular tail
domain of Myo5 can also stabilize the folded and
inhibited conformation of Myo5 through
interaction with the motor domain (10). Myo5a is
highly expressed in neurons (11–12) and has
multiple functions that suggest its involvement in
synaptic plasticity. Myo5a has been detected in
dendrites of Purkinje cells (13–14), presynaptic
terminals of photoreceptor cells (15), intact
synaptosomes from rat cerebral cortex (16), and is
enriched at the postsynaptic density of excitatory
synapses (17). Myo5a is responsible for the
transport of a variety of organelles in axon
terminals and dendritic spines, such as SVs
(18–19) and ER-derived vesicles (20). It also is
likely to be associated with mitochondria (21–22)
and secretory vesicles (23–25). Inhibition of
Myo5a activity causes changes in transport of
axonal vesicles along actin filaments (26–27).
Rab GTPases have been identified in some
cases as link between Myo5 and organelle
transport. In melanocytes, Myo5a is recruited to
melanosomes by Rab27a (28–29) and its effector
melanophilin (30). Previously, direct interactions
have been identified between Rab11a and Rab8a
and the tails of Myo5a and Myo5b (31–33), as well
as between Rab8a and Myo5c tail (12). Most
recently, Rab10 has been shown to associate with
vertebrate class 5 myosins (34). Prime candidates
for such receptors have been identified for
neuronal transport, but a Rab GTPase responsible
for Myo5a recruitment to SVs has not been
determined yet, although Rab3A has been
identified on SVs (3, 35).
Here, we show that the globular tail
domain of Myo5a binds to the brain-specific
GTPase Rab3A. Based on in vitro motility assays
using axoplasm from the squid giant axon, we
found that RabGDI inhibited Myo5a-based vesicle
transport in neurons. Affinity column
chromatography revealed that Rab3A in rat brain
synaptosomal preparations binds to Myo5a tail
domain. Immunofluorescence analysis confirmed
our biochemical findings in cultured frontal cortex
neurons. In addition, sedimentation velocity
analytical ultracentrifugation experiments showed
a direct interaction between highly purified Myo5a
and GTP-bound Rab3A. Together, our data show
that Rab3A and Myo5a can interact directly via its
tail domain on synaptic membranes.
EXPERIMENTAL PROCEDURES
Antibodies
The following commercial primary
antibodies were used in this study: rabbit
polyclonal anti-myosin5a (DIL2, 36), anti-Rab3A
and anti-Rabphilin3A (both from StressGen), anti-
Rab4A and anti-Rab11 (both from Santa Cruz),
anti-GST (GE Healthcare), anti-synapsin 1
(Invitrogen), and mouse monoclonal antibodies
directed against Rab3A (Synaptic Systems),
PSD95 (ABR), actin (Sigma-Aldrich) and kinesin
(Chemicon). Secondary antibodies included anti-
mouse IgG and anti-rabbit IgG labeled with horse-
radish peroxidase (both from Chemicon), and goat-
anti-mouse IgG and goat anti-rabbit IgG labelled
with Alexa 488 or Alexa 594 (Molecular Probes).
Preparation of Squid Brain Clarified Extracts
and In Vitro Motility Assays
Squid (Loligo pealei) were obtained from
the Marine Biological Laboratory in Woods Hole,
MA. Squid optic lobes were dissected from live
animals and either used fresh or frozen in liquid
nitrogen and stored at –80°C.
A whole-cell extract from squid optic
lobes was prepared as described in Brown et al.,
(27). Briefly, optic lobes were homogenized in 1
ml of TBS-I (50 mM Tris, pH 8.0, 150 mM NaCl,
5 mM Na2EDTA, pH 7.0) and centrifuged at
100,000 x g for 10 min at 4°C. The supernatant
was diluted 1:2 in TBST-I (TBS-I, 1% Triton
X-100) and centrifuged again at 100,000 x g for 10
min at 4°C. The Triton X-100 extracted
supernatant is the clarified extract and was used for
affinity column chromatography.
In vitro motility assays from squid
axoplasm were performed as previously described
in Brown et al., (27). Squid giant axons were
dissected from freshly caught squid, placed in
filtered seawater, and then finely dissected in Ca2+-
free seawater. Immediately following the extrusion
of axoplasm, 20 µl TAMD buffer (25 mM Tris, 5
mM ATP, 5 mM MgCl2, 2 mM DTT, pH 7.5)
supplemented with 1 µM rhodamine-phalloidin
(Sigma-Aldrich) was added to each slide. Vesicle
movement was monitored by video-enhanced
contrast differential interference contrast (VEC-
DIC) microscopy, and the presence of actin
filaments was confirmed by fluorescence
microscopy. For motility inhibition experiments,
freshly dissected axons were cut in half; one half
3was extruded onto a coverslip in TAMD buffer
containing GST-RabGDI at  different
concentrations and the other half in TAMD buffer
containing GST as a control.
The level of motile activity (number of
vesicles moving/field/minute) on actin filaments
was determined by counting the total number of
moving vesicles on tracks invisible by VEC-DIC
microscopy. For each preparation, three random
fields (22 µm x 25 µm) at a distance of 20–60 µm
from the bulk axoplasm were selected for analysis.
The number of vesicles moving in each field
during a period of 3 min was counted and averaged
for the three fields. A vesicle was counted each
time it showed continuous directed movement on
an actin track. If a vesicle stopped and then
resumed directed movement in the same or another
direction during the observation period, it was
counted as a new vesicle.
Isolation of Synaptosomes
Rat brains (Sprague-Dawley rats, 7–8
weeks old) from Pel-Freez Biologicals and
C57BL/6J Myo5ad-l20J/d-l20J (null mutant) mouse
brains from McLaughlin Research Institute Animal
Resource Center were obtained frozen and stored
at –20°C until use.
According to the protocols from Carlin et
al., (37) and Jordan et al., (38), synaptosomal
fractions containing pre- and postsynaptic
elements were isolated from adult rat brains and
null mutant mouse brains. Briefly, brains were
homogenized with a motorized Teflon-glass
homogenizer (10 strokes) using 10 g brains/40 ml
solution A (0.32 M sucrose, 1 mM NaHCO3, 1
mM MgCl2, 0.5 mM CaCl2 and 0.2 mg/ml
CompleteTM protease inhibitor cocktail (Roche
Applied Science) and diluted homogenates were
then centrifuged at 1400 x g  for 10 min. The
supernatant solution (S1) was saved, and the pellet
was resuspended in solution A and subjected to
centrifugation (710 x g for 10 min). The resulting
supernates (S2) were pooled and subjected to a
second centrifugation (710 x g  for 10 min).
Supernates (S3) were spun again at 30,000 x g for
20 min to obtain a crude fraction and the pellet
(P4) was resuspended in solution B (0.32 M
sucrose, 1 mM NaHCO3). This homogenate was
layered on top of a three-step sucrose gradient
(0.85 M, 1.0 M, 1.2 M) and centrifuged at 82,500 x
g for 2 hrs. The crude synaptosomal fraction was
collected at the 1.0 M–1.2 M sucrose interface,
resuspended in 4 volumes of solution B and
centrifuged at 48,200 x g  for 20 min. The
supernatant (S5) was discarded, and the resulting
pellet was resuspended in TBS-I. Aliquots were
frozen in liquid nitrogen and stored at –80°C. All
steps during the preparation were carried out on ice
or at 4°C.
Affinity Column Chromatography
GST-Myo5a tail affinity column
chromatography was performed as described in
Brown et al., (27). Briefly, purified GST-Myo5a
tail bacterial lysate was loaded onto a GSTrap
column and washed with PBS. Synaptosomal
fractions prepared from rat and null Myo5a mutant
mouse brains were treated with 0.2 mg/ml
complete protease inhibitor cocktail and 1% Triton
X-100, filtered through a syringe filter unit
(Millipore) and applied to the GST-Myo5a tail
affinity column. The GSTrap column (GE
Healthcare) was washed again with TBS-I and
bound proteins were eluted with 50 mM Tris, pH
8.0, and 10 mM glutathione. Fractions were
collected and analyzed by SDS-PAGE and
Western blots. For GST-RabGDI affinity
isolations, a plasmid containing the full-length
cDNA for Drosophila  GST-RabGDI was
expressed in Escherichia coli (BL21). The 75 kDa
GST-tagged protein was purified on a GST affinity
column and was used in pull down experiments as
stated above.
The effect of the following reagents on
affinity column chromatography was tested: 1 mM
GDP, 1 mM GTP, 1 mM GTPγS, 2 µM
staurosporine (all from Sigma-Aldrich), 20 nM
okadaic acid and 2 µM CaMKIIi (both from
Calbiochem). Triton X-100 treated synaptosomes
were incubated in the presence of GDP, GTP, and
GTPγS and protein kinase/phosphatase inhibitors
for 1 h at room temperature and were then applied
to GST-Myo5a tail or GST-RabGDI affinity
columns.
Cell Culture and Immunocytochemistry
Primary frontal cortex neurons from
embryonic day 15 Shoe/-NRMI or null Myo5a
mutant mice were prepared as described previously
(39). Briefly, frontal cortices were dissociated by
papain enzymatic digestion, and then mechanically
by transfer pipets, and plated on glass coverslips
coated with poly-L-ornithine at 1.0 x 106 cells/ml.
Neurons were prepared for immunofluorescence
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washed with PBS, f ixed with 4%
paraformaldehyde in 4% sucrose containing PBS
for 20 min, treated with 50 mM ammonium
chloride in PBS for 10 min, and permeabilized
with 0.2% Triton X-100 in PBS for 5 min. Primary
(1:100) and secondary (1:300) antibodies were
diluted in 0.2% gelatin in PBS and incubated
successively for 30–60 min at room temperature.
Coverslips were mounted in DABCO (Sigma-
Aldrich) and observed by fluorescence
microscopy.
Protein expression and Purification
All recombinant proteins were individually
expressed in Escherichia coli (Rosetta II,
Novagen) and purified as described previously
(40). Cells were harvested, resuspended in lysis
buffer (50 mM Tris, pH 7.3; 300 mM NaCl; 5 mM
dithiothreitol; 0.2 mg/ml complete protease
inhibitor cocktail), followed by lysis with a
microfluidizer cell disrupter and clarification by
centrifugation. The clarified supernatants
containing the GST-Myo5a tail protein were
passed over a glutathione-Sepharose column
(GSTrapTM FF column, GE Healthcare) and GST-
Myo5a tail was eluted with a gradient of reduced
glutathione. Fractions containing GST-Myo5a tail
were combined, treated with thrombin, and
dialyzed with three changes against PBS
containing 5 mM dithiothreitol. Myo5a tail was
further purified over a glutathione-Sepharose
column followed by gel filtration chromatography.
The GFP-Rab3A construct (41) was PCR-
subcloned into the pHis parallel vector (42), and
purified by nickel affinity chromatography
(HisTrap column, GE Healthcare) followed by
dialysis and TEV protease treatment, and further
purification over a HisTrap column. Finally, all
proteins were further purified using a gel filtration
column (Superdex 200, GE Healthcare) pre-
equilibrated with 20 mM Tris (pH 7.5), 300 mM
NaCl, 1 mM TCEP, and 1 µM ZnCl2.
Analytical Ultracentrifugation
Analytical ultracentrifugation experiments
were carried out as previously described (43). A
ProteomeLabTM XL-A analytical ultracentrifuge
(Beckman Coulter) equipped with absorbance
optics and an eight-hole An-50 Ti analytical rotor
was used for sedimentation experiments that were
carried out at 10°C and 50,000 rpm (200,000 x g)
using 3-mm two-sector charcoal-filled Epon
centerpieces with quartz windows. For each
protein sample, 300 scans were collected in a
period of ~ 11 hrs. Sedimentation boundaries were
analyzed by the continuous sedimentation
coefficient distribution (c(s)) method using the
program SEDFIT (44).
Quantitative Analysis
Images for quantitative analysis were
saved as PICT files from high-resolution scanned
scientific imaging films (Kodak). Image Gauge
software (Fujifilm Inc.) was used to measure pixel
intensities (grayscale intensities) of proteins
detected by Western blot analysis. Measurements
of proteins bound to GST-Myo5a tail or GST-
RabGDI were individually normalized against the
background of each individual film and
renormalized against the signal obtained with the
same proteins in synaptosomes. The resulting
individual, normalized signal intensities were
averaged for each experiment and analyzed by a
two-tailed t-test.
RESULTS
RabGDI inhibits Myo5a-based vesicle motility.
In vitro motility assays were performed to
determine whether a Rab GTPase is involved in
neuronal Myo5a-based vesicle transport (27).
Axoplasm from the squid giant axon was treated
with bacterially expressed Rab GDP dissociation
inhibitor (RabGDI). In axoplasm preparations on
glass coverslips, actin spontaneously assembled
into filaments, forming a network on the coverslip
surface. For these experiments, each axon was
divided in half; one half was incubated in buffer
containing RabGDI at concentrations between 1
and 20 µM RabGDI and the other half in buffer
containing GST (Fig. 1A). GST, which had no
effect, was used as a control at identical
concentrations as RabGDI and referred to as 0 µM
(supplemental Video 1). The axoplasmic actin
filament network was stable and did not change in
the presence of GST-RabGDI during observation
time (Fig. 1B). Vesicle movement was observed in
the presence of ATP and motile activity was
measured as the number of moving
vesicles/field/min. RabGDI inhibited the motile
activity in a concentration-dependent manner (Fig.
1A), and motile activity was inhibited by 99% in
5the presence of 20 µM RabGDI (Fig. 1A ,
supplemental Video 2).
We then used GST-RabGDI as a matrix
for affinity chromatography to isolate GDP-bound
Rab GTPases. Clarified squid brain homogenate
prepared from squid optic lobes was saturated with
1 mM GDP and applied to an immobilized
RabGDI affinity column. Bound proteins were
eluted with glutathione, then analyzed by SDS-
PAGE and Western blots. As a control, GDP-
loaded brain homogenate was applied to a GSTrap
column to which RabGDI was omitted. The
presence of the 75 kDa GST-RabGDI fusion
protein was confirmed by immunoblotting (Fig.
1C, lane 1). Among the proteins specifically eluted
from RabGDI affinity column, we identified
Rab3A (Fig. 1C, lane 2). These data demonstrated
that Myo5-based neuronal vesicle transport (27)
depends on an active Rab GTPase and that native
Rab3A is present in brain homogenates. Thus, our
data are consistent with findings that Rab3A is
expressed in squid brain and is present on SVs
(35).
Rab3A/Rabphilin3A complex is a novel Myo5a
binding partner.
To identify the Rab GTPase that interacts
with Myo5a at the synapse, the synaptosomal
fraction isolated from rat brains rather than whole-
brain homogenate was used in affinity isolation
experiments. The synaptosomal fraction
(Supplemental Fig. 1) was loaded onto GST-
tagged Myo5a tail affinity columns prepared as
described (27) and the bound proteins (BP) were
eluted with glutathione (Fig. 2A). We tested the
ability of the GST-tagged fragment of the globular
tail domain of mouse Myo5a to pull down native
kinesin from synaptosomes to verify its
functionality (45). As expected, kinesin was
identified in eluates obtained from GST-Myo5a
tail affinity columns (Fig 2B). Because of the
knowledge that Rab3A is a major presynaptic
protein, we tested proteins specifically eluted from
GST-Myo5a affinity columns for the presence of
Rab3A, which was confirmed by immunoblotting
(Fig. 2B). We also identified the putative Rab3A
effector protein Rabphilin3A in chromatographic
eluates. These data suggested that the recombinant
Myo5a tail forms a complex with native Rab3A
and Rabphilin3A. In control experiments, the
synaptosomal fraction was loaded onto a GSTrap
column to which only GST was applied. No
binding of synaptosomal proteins to affinity
columns was detected (Supplemental Fig. 2).
Rab4A and Rab11, Rabs shown to be involved in
membrane trafficking and sorting of endocytosed
material between different cell compartments,
were not present in the eluates as revealed by
Western blots. However, Rab11 has been shown to
bind to another member of the myosin-V family,
Myo5b, in neurons (46).
We next determined whether Myo5a tail
association with Rab3A is GTP-dependent.
Synaptosomal fractions preincubated with either 1
mM GDP alone or 1 mM GTP in the presence of 1
mM GTPγS were loaded onto Myo5a tail affinity
columns. Bound proteins were eluted and their
levels in eluates were measured biochemically by
Western blots and normalized against background
intensities and signal intensities obtained with
proteins in synaptosomes. Incubation of the
synaptosomal fraction with GDP increased the
amount of both Rab3A and Rabphilin3A bound to
RabGDI (Fig. 2C, left panel, Fig. 2D, left panel,
respectively). Activation of Rab3A with GTP in
the presence of GTPγS increased binding affinity
of Rab3A (Fig. 2C , right panel) and Rabphilin3A
(Fig. 2D, right panel) to Myo5a tail. In conclusion,
these data indicate that Myo5a tail associates with
Rab3A in a complex with Rabphilin3A in a GTP-
dependent manner.
Protein kinase activity regulates association of
Myo5a with Rab3A.
We next tested for a requirement for
protein phosphorylation for Myo5a tail association
with Rab3A. Synaptosomes were first treated with
2 µM staurosporine, a broad-spectrum inhibitor of
protein kinases, and analyzed by Myo5a tail
affinity chromatography. This treatment inhibited
Rab3A binding to the Myo5 tail by 50% as
revealed by Western blots of eluted fractions (Fig.
3). Treatment with 20 nM okadaic acid, an
inhibitor of protein phosphatase 1 and 2A,
increased the binding activity of Rab3A to Myo5a
tail by 90% (Fig. 3). Surprisingly, the addition of 2
µM CaMKII inhibitory peptide did not affect the
association of Rab3A to the Myo5a tail (Fig. 3).
The addition of protein kinase inhibitors had no
significant effect on Myo5a tail as determined by
quantitative Western blot analysis (data not
shown). These results suggest that CaMKII as well
as other protein kinases may be involved in
6regulating the interaction of Myo5a and Rab3A on
SVs.
The tail of Myo5a binds to Rab3A in dilute-lethal
(Myo5ad-l/d-l/Myo5ad-l/d-l) synaptosomes.
To exclude the possibility that the
interaction between Myo5a and Rab3A is through
a tail/tail interaction between recombinant and
native Myo5a in the synaptosomal fraction, we
used a synaptosomal fraction isolated from dilute-
lethal homozygous null mutant mouse brains
(Myo5ad-l/d-l/Myo5ad-l/d-l) lacking Myo5a. These
dilute-lethal null mutant mice exhibit impaired
melanosome transport and pronounced
neurological symptoms (11). First, we compared
the protein composition of wild-type and null
mutant synaptosomes by Western blots.
Biochemical characterization revealed that both
brain fractions were similar, except for the
expected absence of Myo5a in null mutant
synaptosomes (Fig. 4A). Surprisingly, the detected
amounts of actin and kinesin were significantly
higher in null mutant preparations contrasted with
wild-type synaptosomes (Fig. 4A).
We next performed affinity isolation
experiments using the GST-Myo5a tail. In null
mutant chromatographic eluates we detected not
only kinesin but also Rab3A, whereas
Rabphilin3A was not detectable (Fig. 4B). The
association of Myo5a tail and Rab3A from null
mutant synaptosomes also was GTP-dependent as
revealed by RabGDI column affinity
chromatography (Fig. 4C). In conclusion, our data
show that Rab3A from Myo5a-deficient null
mutant synaptosomes interacts with the
recombinant Myo5a tail and that Rab3A from
mutant mice behaves similarly to Rab3A from
wild-type synaptosomes.
Myo5a associates with Rab3A in neuronal
cultures.
To investigate the association and
functional relevance between Myo5a and Rab3A
in vivo, we cultured frontal cortex neurons that
were isolated from wild-type and null mutant
mouse brains. Using double immunofluorescence
microscopy, we analyzed whether Myo5a is
codistributed with Rab3A in these neuronal
cultures. Both proteins exhibited a punctate
staining pattern in the soma and neurites and
strong colocalization was detected between Myo5a
and Rab3A in neurites of wild-type neurons by
linescan analysis (Fig. 5A  and 5A ’). Next, the
distribution of Rab3A was assessed in null mutant
neurons and compared to that of wild-type neurons.
Null mutant neurons grew and extended neurites
normally in culture and Rab3A had a staining
pattern that was comparable to that in wild-type
neurons in the absence of Myo5a (Fig. 5B). No
colocalization was detected between Myo5a and
Rab3A immunoreactivity in null mutant neurons
(Fig. 5B’).
To determine whether areas of Myo5a and
Rab3A colocalization corresponded to SVs, we
analyzed the distribution of Rab3A and the SV
marker synapsin 1 in wild-type and null mutant
mouse neurons (Supplemental Figure 3). We found
that Rab3A and synapsin 1 colocalized in neurites
of wild-type neurons (Supplemental Figure 3A) and
that both proteins showed partial colocalization in
some areas of null mutant neurons (Supplemental
Figure 3B).
Myo5a tail interacts directly with Rab3A.
To determine if Rab3A interacts directly
with Myo5a tail, sedimentation velocity analytical
ultracentrifugation (AUC) was performed on
highly purified recombinant Myo5a tail and
Rab3A (Fig. 6A). Sedimentation velocity profiles
for the purified samples were fitted to a
distribution of Lamm equation solutions to
determine the diffusion-free sedimentation
coefficient distribution (c(s)) for each protein (Fig.
6B  and C and Table 1) (44). The sedimentation
velocity profile for 2.6 µM Rab3A showed a
mostly monodisperse distribution in solution that
sedimented with an s value of 1.90 ± 0.3 and an
experimentally determined molecular mass of 23.5
kDa (Fig. 6B and Table 1). In contrast, 0.51 µM
Myo5a tail sedimented as two distinct species with
s values of 3.4 ± 1.5 and 5.1 ± 0.8 as displayed in
the sedimentation velocity profile (Fig. 6C).
Modeling of the sedimentation coefficients
identified two distinct peaks representing
monomeric (61.5%, 3.4 ± 1.5) and dimeric (38.5%,
5.1 ± 0.8) species of the Myo5a tail (Fig. 6C and
Table 1). The molecular masses calculated from
the sedimentation coefficients were 52.9 kDa for
the monomeric and 96.8 kDa for the dimeric
species of Myo5a tail very similar to that of the
theoretical molecular masses for the monomer and
dimer (54.7 kDa and 109.4 kDa) (Table 1). To
characterize the interaction between Rab3A and
Myo5a tail, 2.6 µM Rab3A and 0.51 µM Myo5a
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were determined in the presence of GDP or
GTPγS. When both proteins were mixed in the
presence of 1 mM GTPγS, a direct interaction was
observed and the protein-protein complex
sedimented with s values of 4.3 ± 1.3 and 5.9 ± 0.6
(Fig. 6D and Table 1). These results suggest a
direct interaction between Myo5a tail and GTP-
bound Rab3A. Further analysis revealed the
presence of excess free Rab3A (67%) and that
GTP-bound Rab3A interacts with both the
monomeric (27.5%) and dimeric (5.5%) species of
the Myo5a tail (Fig. 6D). The experimentally
obtained molecular masses were 73.8 kDa for a
complex between GTP-bound Rab3A and
monomeric Myo5a tail, and 135 kDa for a
complex containing GTP-bound Rab3A and
dimeric Myo5a tail (Table 1). These masses are
similar to theoretical molecular masses for a 1:1
complex between Rab3A and the Myo5a tail
monomer at 4.3S*, and a 1:2 complex between
Rab3A and the Myo5a tail dimer at 5.9S *.
However, Myo5a tail and Rab3A sedimented as
separate species in the presence of 1 mM GDP
(Fig. 6D).
DISCUSSION
Neurotransmission, the process by which
neurons communicate with their target cells,
requires a balance between endocytosis and
exocytosis of SVs. The release of neurotransmitter
relies on SV trafficking, which involves the
coordinated activity of many proteins including
small GTP-binding proteins. Previous studies have
established that Rab3A, a highly abundant small
GTPase on brain SVs in the presynaptic nerve
terminal, controls the Ca2+-mediated release of
neurotransmitter (47–48). However, it is not well
understood whether and how SVs are actively
transported between different compartments in the
presynaptic nerve terminal. In this study we
confirmed that Myo5a tail associates with SVs in
the rat brain synaptosomal fraction and we showed
for the first time that the globular tail domain of
recombinant Myo5a forms a complex with Rab3A
in a GTP-dependent manner. We further
demonstrated that purified Rab3A in its GTP-
bound form interacts directly with both monomeric
and dimeric species of Myo5a tail. Therefore, we
conclude that Rab3A is the receptor for Myo5a on
SVs.
The findings in this report add to the
established roles for Rab3A. It is well known that
Rab3A regulates SV trafficking including
targeting, fusion, and repriming of SVs after
exocytosis, and regulates the dynamics of the actin
cytoskeleton (49). The cycling of Rab3A between
the active GTP-bound or inactive GDP-bound
form is associated with changes in the trafficking
cycle of SVs at presynaptic nerve terminals. In its
GTP-bound form Rab3A is largely associated with
SVs at the synapse, while GTP-hydrolysis has
been linked to Ca2+-dependent exocytosis resulting
in the dissociation of Rab3A from SVs (50–52).
After fusion with the plasma membrane, SVs are
retrieved through endocytosis followed by
reassociation of Rab3A with SVs, a process that is
facilitated by RabGDI (5, 53). Stimulation of
synaptic terminals by chemical depolarization
resulted in the redistribution of SVs from the
readily releasable pool towards the active zone
(54). This process is completely blocked in RAB3A
knock-out mice indicating an active role for
Rab3A in SV trafficking (55).
Our results help to answer one of the key
questions of myosin driven vesicle transport in
neurons, i.e. how the motor binds to vesicles. It has
been shown that Myo5a functions in axonal vesicle
transport on actin filaments (20). Even though
Myo5a has been implicated in the regulation of
secretory vesicle trafficking its interaction with
Rab3A had not been established previously.
Studies of Myo5a in different cell types shows that
this motor is involved in the capture of vesicles
and their actin-based transport, as well as in late
steps in exocytosis (56). Thus, our results support
the idea that GTP-bound Rab3A is involved in
Myo5a-dependent vesicle transport.
Distinct members of the Rab family are
often used by unconventional myosin motors to
attach to their cargo, to regulate the motor activity,
and to mediate vesicle transport along actin
filaments (57–58). Therefore, the formation of the
Myo5a/Rab3A complexes is likely to be a critical
step that is required for the correct binding,
translocation, and delivery of cargoes to the
plasma membrane. The Rab27a/Myo5a interaction
was the first evidence for the association of a Rab
GTPase and a myosin. Rab27a is present at the
surface of mature melanosomes and recruits
Myo5a via Melanophilin/Slac-2, which regulates
its motor activity (29–30, 59–60). Therefore,
melanophilin is required as a linker protein that
8targets Myo5a to melanosomes. Rab3A has
multiple binding partners and therefore multiple
functions. A number of Rab effector proteins
including Rabphilin3A contain a Rab-binding
domain and a linker domain, which can interact
with the target membrane. As shown in earlier
studies, Rab3A recruits Rabphilin3A to SVs before
docking to the plasma membrane and
neurotransmitter release (5). In this study, we
showed that Myo5a forms a complex with Rab3A
and Rabphilin3A on SVs. However, in contrast to
Myo5a attachment to melanosomes, we found that
the globular tail domain of Myo5a interacts
directly with GTP-bound Rab3A on SVs and that
Rabphilin3A may not be required for binding of
Rab3A to the Myo5a tail. Furthermore,
Rabphilin3A is not needed for the regulatory
functions of Rab3A in neurotransmitter release as
demonstrated in Rabphilin knock-out mice (61).
Similarly, Myo5b associates with Rab11a
in a GTP-dependent manner and regulates a step in
plasma membrane recycling. This interaction is
facilitated by the Rab11 family-interacting protein-
2 (Rab11-FIP-2), which links the Myo5b tail to
Rab11a and regulates endosome movement (31,
62). Moreover, Rab11 was shown to interact with
Myo5b and regulate AMPA receptor trafficking
(46). Myo5c, the third member of the vertebrate
class 5 myosins, has been shown to interact with
the transferrin receptor and Rab8a, which regulates
the biosynthetic pathway between the Golgi
apparatus and the plasma membrane (12). In
addition, Roland et al. (32) demonstrated the
interaction of Myo5b with Rab8a in compartments
containing EHD protein family members in the
absence of Rab11a (32). More recently, the same
group used dominant-negative Myo5 tail
constructs to confirm the interaction of all three
vertebrate class 5 myosins with Rab8a and Rab10
(34). Furthermore, they showed that multiple Rab
GTPases could regulate all class 5 myosins.
Although Myo5a has been shown to bind
to SVs that contain Rab3 those results did not
demonstrate a direct binding between both proteins
(18). When we reconstituted the protein-protein
interaction with highly purified recombinant
mouse Myo5a tail and human Rab3A, our
functional results showed a direct interaction
between the AF-6/cno-homology tail region of
Myo5a and Rab3A. As Myo5a tail did not bind to
nucleotide-free Rab3A, the data indicated that this
interaction is strongly GTP-dependent. We also
found that GTP-bound Rab3A binds at a 1:1
stochiometry to the monomeric Myo5a tail in the
monomeric form, and at 1:2 stochiometry to the
Myo5a tail in the dimeric form. At present, the
exact nature of the protein-protein interaction in
the monomeric and dimeric forms of Myo5a is not
clear. We speculate that binding of Rab3A to
monomeric Myo5a is favored, which could be
explained by the lower Kd value for GTP-bound
Rab3A and Myo5a tail monomer interaction as
compared to GTP-bound Rab3A and the Myo5a
tail dimer interaction. Future studies that
distinguish among these possibilities will be
required to understand this protein-protein
interaction in neuronal cells.
Protein-protein interactions are important
key events for the correct targeting of proteins and
the precise timing of exocytosis in nerve terminals.
In a recent study coming from Giovedi et al., (8),
synapsin 1 has been identified as a binding partner
of SV-associated Rab3A. Synapsin 1 was
originally identified as a phosphoprotein that
cross-links the reserve pool of SV away from the
active zone (63). When synapsin 1 becomes
phosphorylated by CaMKII, its affinity for SVs
and Rab3A is greatly reduced which causes the
release of SVs from the actin cytoskeleton (8, 64).
However, studies of Myo5a in synaptosomes
isolated from rat hippocampi showed that Myo5a
did not bind directly to synapsin 1 (18). These data
were interpreted to suggest that Myo5a could bind
to SVs that are mobilized after release from
synapsin/actin interactions. In additional cross-
linking experiments, the same authors identified
the synaptobrevin II/synaptophysin complex as a
preliminary binding partner for Myo5a on SVs
(18).
Our data provide evidence for a Myo5a tail
association with Rab3A on SVs in vitro and are
consistent with the model presented in Fig. 7. We
suggest that GTP-bound Rab3A binds directly to
the AF-6/cno-homology tail region of Myo5a and
associates with Rabphilin3A on SVs (Fig. 7A).
After GTP hydrolysis caused by Ca2+-induced
exocytosis the GDP-bound form Rab3A is then
released from the Myo5a tail, where it then binds
to RabGDI to undergo GDP/GTP exchange (Fig.
7B). After release from RabGDI, the GTP-bound
or active form of Rab3A can associate with SVs
again and bind to Myo5a or putative effector
proteins such as Rabphilin 3A (5). What could be a
possible function for Myo5a in SV transport and
9synaptic transmission? It has been shown that
Myo5a is important in recycling and replenishing
of synaptic or neurosecretory vesicles (18, 23, 26,
65). Furthermore, the subcelluar localization of
Myo5a in neurons suggests several roles in
synaptic physiology as shown for photoreceptor
cells in the retina (66). Our findings support the
idea that Myo5a is an important factor for Rab3A-
mediated synaptic transmission including SV
availability, because neurotransmitter release is
regulated by multiple steps, which includes the
release of SVs from the actin cytoskeleton,
docking to the presynaptic plasma membrane
followed by exocytosis.
In conclusion, we have shown that the tail
domain of Myo5a forms a complex with Rab3A on
SVs in vitro. Biochemical and kinetic studies
demonstrated a direct GTP-dependent interaction
between Myo5a and Rab3A. A further
characterization of Myo5a binding to SVs and the
identification of additional binding partners will




1. Jahn, R., and Südhof, T.C. (1994) Annu. Rev. Neurosci. 17, 219–246
2. Geppert, M., Bolshakov, V.Y., Siegelbaum, S.A., Takei, K., De Camilli, P., Hammer, R.E., and
Südhof, T.C. (1994) Nature 369, 493–497
3. Schlüter, O.M., Khvotchev, M., Jahn, R., and Südhof, T.C. (2002) J. Biol. Chem. 277, 40919–40929
4. Fischer von Mollard, G., Stahl, B., Li, C., Südhof, T.C., and Jahn, R. (1994) Trends Biochem. 19,
164–169
5. Stahl, B., Chou, J.H., Li, C., Südhof, T.C., and Jahn, R. (1996) EMBO J. 15, 1799–1809
6. Wang, Y., Okamoto, M., Schmitz, F., Hofmann, K., and Südhof, T.C. (1997) Nature 388, 593–598
7. Brondyk, W.H., McKiernan, C.J., Fortner, K.A., Stabila, P., Holz, R.W., and Macara, I.G. (1995) Mol.
Cell Biol. 15, 1137–1143
8. Giovedi, S., Vaccaro, P., Valtorta, F., Darchen, F., Greengard, P., Cesareni, G., and Benfenati, F.
(2004) J. Biol. Chem. 279, 43760–43768
9. Desnos, C., Huet, S., and Darchen, F. (2007) Biol. Cell. 99, 411–423
10. Trybus, K.M. (2008) Cell. Mol. Life Sci. 65, 1378–1389
11. Mercer, J.A., Seperack, P.K., Strobel, M.C., Copeland, N.G, and Jenkins, N.A. (1991) Nature 349,
709–713
12. Rodriguez, O.C., and Cheney, R.E. (2002). J. Cell Sci. 115, 991–1004
13. Dekker-Ohno, K., Hayasaka, S., Takagishi, Y., Oda, S., Wakasugi, N., Mikoshiba, K., Inouye, M.,
and Yamamura, H. (1996) Brain Res. 714, 226–230
14. Takagishi, Y., Oda, S., Hayasaka, S., Dekker-Ohno, K., Inouye, M., and Yamamura, H. (1996)
Neurosci. Lett. 215, 169–172
15. Schlamp, C.L., and Williams, D.S. (1996) Exp. Eye Res. 63, 613–619
16. Mani, F., Espreafico, E.M., and Larson, R.E. (1994) Braz. J. Med. Biol. Res. 27, 2639–2643
17. Walikonis, R.S., Jensen, O.N., Mann, M., Provance, D.W. Jr, Mercer, J.A., and Kennedy, M.B. (2000)
J. Neurosci. 20, 4069–4080
18. Prekeris, R., and Terrian, D.M. (1997) J. Cell Biol. 137, 1589–1601
19. Evans, L.L., Lee, A.J., Bridgman, P.C., and Mooseker, M.S. (1998) J. Cell Sci. 111, 2055–2066
20. Tabb, J.S., Molyneaux, B.J., Cohen, D.L., Kuznetsov, S.A., and Langford, G.M. (1998) J. Cell Sci.
111, 3221–3234
21. Morris, R.L., and Hollenbeck, P.J. (1995) J. Cell Biol. 131, 1315–1326
22. Pahtak, D., Sepp, K.J., and Hollenbeck, P.J. (2010) J. Neurosci. 30, 8984–8992
23. Rose, S.D., Lejen, T., Casaletti, L., Larson, R.E., Pene, T.D., and Trifaro, J.M. (2003) J. Neurochem.
85, 287–298
24. Rudolf, R., Kögel, T., Kuznetsov, S.A., Salm, T., Schlicker, O., Hellwig, A., Hammer III, J.A., and
Gerdes, H.H. (2003) J. Cell Sci. 116, 1339–1348
25. Desnos, C., Huet, S., Fanget, I., Chapuis, C., Böttiger, C., Racine, V., Sibarita, J-B., Henry, J-P., and
Darchen, F. (2007) J. Neurosci. 27, 10636–10645
26. Bridgman, P.C. (1999) J. Cell Biol. 146, 1045–1060
27. Brown, J., Stafford, P., and Langford, G.M. (2004) J. Neurobiol. 58, 175–188
28. Bahadoran, P., Aberdam, E., Mantoux, F., Buscà, R., Bille, K., Yalman, N., de Saint-Basile, G.,
Casaroli-Marano, R., Ortonne, J.P., and Balloti, R. (2001) J. Cell Biol. 152, 843–850
29. Wu, X.S., Rao, K., Zhang, H., Wang, F., Sellers, J.R., Matesic, L.E., Copeland, N.G., Jenkins, N.A.,
and Hammer, J.A. III. (2002) Nat. Cell Biol. 4, 271–278
30. Provance, D.W., James, T.L., and Mercer, J.A. (2002) Traffic 3, 124–132
31. Lapierre, L.A., Kumar, R., Hales, C.M., Navarre, J., Bhartur, S.G., Burnette, J.O., Provance, D.W. Jr,
Mercer, J.A., Bähler, M., and Goldenring J.R. (2001) Mol. Biol. Cell 12, 1843–1857
32. Roland, J.T., Kenworthy, A.K., Peranen, J., Caplan, S., and Goldenring, J.R. (2007) Mol. Biol. Cell
18, 2828–2837
33. Correia, S.S., Bassani, S., Brown, T.C., Lise, M.F., Backos, D.S., El-Husseini, A., Passafora, M., and
Esteban, J.A. (2008) Nat. Neurosci. 11, 457–466
11
34. Roland, J.T., Lapierre, L.A., and Goldenring, J.R. (2009) J. Biol. Chem. 284, 1213–1223
35. Chin, G.J., and Goldman, S.A. (1992) Brain Res. 571, 89–96
36. Wu, X., Bowers, B., Wei, Q., Kocher, B., and Hammer, J.A. III. (1997) J. Cell Sci. 110, 847–859
37. Carlin, R.K., Grab, D.J., Cohen, R.S., and Siekevitz, P. (1980) J. Cell Biol. 86:831–845
38. Jordan, B.A, Fernholz, B.D., Boussac, M., Xu, C., Grigorean, G., Ziff, E.B., and Neubert, T.A. (2004)
Mol. Cell. Proteomics 3.9, 857–871
39. Gramowski, A., Jügelt, K., Stüwe, S., Schulze, R., McGregor, G.P., Demand-Wartenberg, A., Loock,
J., Schröder, O., and Weiss, D.G. (2006) Eur. J. Neurosci. 24, 455–465
40. Patel, A., Vought, V.E., Dharmarajan, V., and Cosgrove, M.S. (2008) J. Biol. Chem. 283 ,
32162–32175
41. Waselle, L., Coppola, T., Fukuda, M., Iezzi, M., El-Amraoui, A., Petit, C., and Regazzi, R. (2003)
Mol. Biol. Cell 14, 4103–4113
42. Sheffield, P., Garrard, S., and Derewenda, Z. (1999) Protein Expr Purif. 15, 34-39
43. Patel, A., Dharmarajan, V., Vought, V.E., and Cosgrove, M.S. (2009) J. Biol. Chem. 284 ,
2424–224256
44. Schuck, P. (2000) Biophys. J. 78, 1606–1619
45. Huang, J-D., Brady, S.T., Richards, B.W., Stenoien, D., Resau, J.H., Copeland, N.G., and Jenkins,
N.A. (1999) Nature 397, 267–270
46. Lise, M-F., Wong, T.P., Trinh, A., Hines, R.M., Liu, L., Kang, R., Hines, D.J., Lu, J., Goldenring,
J.R., Wang, Y.T., and El-Husseini, A. (2006) J. Biol. Chem. 281, 3669–3678
47. Fischer von Mollard, G., Mignery, G.A., Baumert, M., Perin, M.S., Hanson, T.J., Burger, P.M., Jahn,
R., and Südhof, T.C. (1990) Proc. Nat. Acad. Sci. USA. 87, 1988–1992
48. Geppert, M., Goda, Y., Stevens, C.F., and Südhof, T.C. (1997) Nature 387, 810–814
49. Jahn, R., Lang, T., and Südhof, T.C. (2003) Cell 112, 519-533
50. Fischer von Mollard, G., Südhof, T.C., and Jahn, R. (1991) Nature 349, 79–81
51. Stahl, B., von Mollard, G.F., Walch-Solimena, C., and Jahn, R. (1994) J. Biol. Chem. 269,
24770–24776
52. Star, E.N., Newton, A.J., and Murthy, V.N. (2005) J. Physiol. 569, 103–117
53. Chou, J.H., and Jahn, R. (2000) J. Biol. Chem. 275, 9433–9440
54. Leenders, A.G., Lopes Da Silva, F.H., Ghijsen, W.E., and Verhage, M. (2001) Mol. Biol. Cell 12,
3095–3102
55. Schlüter, O.M., Schmitz, F., Jahn, R., Rosenmund, C., and Südhof, T.C. (2004) J. Neurosci. 24 ,
6629–6637
56. Eichler, T.W., Kögel, T., Bukoreshtliev, N.V., and Gerdes, H.H. (2006) Biochem. Soc. Trans. 34,
671–674
57. Jordens, I., Marsman, M., Kuijl, C., and Neefjes, J. (2005) Traffic 6, 1070–1077
58. Grosshans, B.L., Ortiz, D., and Novick, P. (2006) Proc. Natl. Acad. Sci. USA. 103, 11821–11827
59. Matestic, L.E., Yip, R., Reuss, A.E., Swing, D.A., O’Sullivan, T.N., Fletcher, C.F., Copeland, N.G.,
and Jenkins, N.A. (2001) Proc. Natl. Acad. Sci USA. 98, 10238–10243
60. Li, X-D., Ikebe, R., and Ikebe, M. (2005) J. Biol. Chem. 280, 17815–17822
61. Schlüter, O.M., Schnell, E., Verhage, M., Tzonopoulos, T., Nicoll, R.A., Janz, R., Malenka, R.C.,
Geppert, M., and Südhof, T.C. (1999) J. Neurosci. 19, 5834–5846
62. Hales, C.M., Vaerman, J.P., and Goldenring, J.R. (2002) J. Biol. Chem. 277, 50415–50421
63. Landis, D.M., Hall, A.K., Weinstein, L.A., and Reese, T.S. (1988) Neuron 1, 201–209
64. Turner, K.M., Burgoyne, R.D., and Morgan, A. (1999) Trends Neurosci. 22, 459–464
65. Schnell, E., and Nicoll, R.A. (2001) J. Neurophysiol. 85, 1498–1501
66. Libby, R.T., Lillo, C., Kitamoto, J., Williams, D.S., and Steel, K.P. (2004) J. Cell Sci. 117, 4509–4515
12
Acknowledgements–This work was supported by NSF grant MCB-0517303 (G.M.L.) and NIH grants
CA140522 (M.S.C.), GM066901 and TW007220 (J.A.M. and D.P.W.). We thank Carl DeSelm
(Washington University, St. Louis, MO) and Jeremiah Brown (Dartmouth Medical School, Hanover, NH)
for experimental design and technical assistance with preparation of squid brain extracts and in vitro
motility assays. We thank Bärbel Redlich (University of Rostock, Rostock, Germany) for help with
culture and immunostaining of mouse frontal cortex neurons and Venkatasubramanian Dharmarajan
(Syracuse University, Syracuse, NY) for technical assistance with protein purification. We thank Romano
Regazzi (University of Lausanne, Lausanne, Switzerland) for the GFP-Rab3A construct.
6 The abbreviations used are: synaptic vesicles, SVs; myosin-Va, Myo5a; calmodulin-dependent kinase II
CaMKII; GDP dissociation inhibitor, GDI
FIGURE LEGENDS
Figure 1: Myo5a-dependent neuronal vesicle motility requires a Rab GTPase.
A, Vesicle motility in squid axoplasm was inhibited by 99% at 20 µM GST-RabGDI compared to controls
(0 µM). All data are mean ± SD of three independent experiments. B, 20 µM GST-RabGDI did not affect
actin filament network formation as visualized by fluorescence microscopy after incubation with 0.5 µM
rhodamine-phalloidin. Bar, 5 µm. C, GST-RabGDI was used in an affinity column to isolate Rab GTPases
from squid brain. Western blots of eluted fractions probed with antibodies to GST (lane 1) and Rab3A
(lane 2) revealed the presence of Rab3A. Rab3A was not present if no RabGDI was applied to affinity
column (lane 3).
Figure 2: Rab3A is a novel Myo5a binding partner.
A, The synaptosomal fraction (Syn) and bound proteins (BP) eluted from immobilized GST-Myo5a tail
affinity column were analyzed by SDS-PAGE stained with Coomassie. GST-Myo5a tail (84 kD) and GST
(25 kD) are indicated. B, Western blots of the synaptosomal fraction (Syn) and bound proteins (BP) eluted
from GST-Myo5a tail affinity column are shown. Blots were probed for proteins as indicated. Rab3A was
detected in the eluted fraction. C–D, Rab3A and Rabphilin3A bind to Myo5a tail in a GTP-dependent
manner. Inactive GDP-bound Rab3A (C, left panel) and Rabphilin3A (D, left panel) bind to RabGDI.
Active GTP-bound Rab3A (C, right panel) and Rabphilin3A (D, right panel) bind to Myo5a tail in the
presence of GTPγS. Signal intensities of Rab3A and Rabphilin3A were individually normalized against
the signal obtained with these proteins in synaptosomes. All data are mean ± SD of three independent
experiments. Statistically significant differences at P < 0.001 are indicated by asterisks (*).
Figure 3: Protein kinase activity regulates the association of Myo5a with Rab3A.
Synaptosomal fractions were preincubated with 2 µM staurosporine (Stauro), 2 µM CaMKII inhibitory
peptide (CaMKIIi) or 20 nM okadaic acid (OA) and then passed over a GST-Myo5a tail affinity column.
Western blots of the total amount of Rab3A or Rabphillin3A (Syn) and bound proteins (BP) eluted from
GST-Myo5a tail affinity column are shown. 2 µM of staurosporine (Stauro) decreased binding of Rab3A
and Rabphilin3A to GST-Myo5a column. Inhibition of CaMKII activity did not affect the binding affinity
of Rab3A to Myo5a tail but reduced Rabphilin3A binding. Inhibition of protein phosphatases 1 and 2A
increased binding affinity of both Rab3A and Rabphilin3A to Myo5a tail (OA). Signal intensities of
Rab3A and Rabphilin3A were individually normalized against the signal obtained with these proteins in
synaptosomes. All data are mean ± SD of three independent experiments. Statistically significant
differences compared with the controls are indicated by *P < 0.001.
Figure 4: Myo5a is absent from Myo5ad-l/d-l synaptosomes as detected by Western blot analysis.
A, Comparison of major proteins present in rat wild type synaptosomes (Wt) and mouse dilute-lethal
synaptosomes (Myo5ad-l/d-l). Western blots revealed the presence of Rab3A, Rabphilin3A, and
synaptophysin in both synaptosomal preparations, whereas Myo5a is absent in Myo5ad-l/d-l synaptosomes.
B, Western blots of bound proteins (BP) eluted from GST-Myo5a tail affinity columns probed for proteins
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as indicated. C, Rab3A from Myo5ad-l/d-l null mutant synaptosomes binds to Myo5a tail in a GTP-
dependent manner. Inactivation of Rab3A in the presence of GDP resulted in binding of Rab3A (C, left
panel) to RabGDI. Activation of Rab3A with GTP in the presence of GTPγS decreased binding affinity of
Rab3A to RabGDI (C, right panel). Rabphilin3A could not be detected by Western blot analysis.
Figure 5: The association of Myo5a with Rab3A is altered in mouse dilute-lethal (Myo5ad-l/d-l)
neurons.
A-B, Indirect immunofluorescent localization of Myo5a (green) and Rab3A (red) in 12 DIV wild-type (A)
and 6 DIV dilute-lethal Myo5ad-l/d-l (B ) mouse frontal cortex neurons. A’–B’, The insets show a high
magnification of a dendritic segment where colocalization between Myo5a and Rab3A was detectable in
wild-type (A’) but absent in dilute-lethal Myo5ad-l/d-l neurons (B’). Fluorescence intensity was measured for
Myo5a (green) and Rab3A (red) along the dendrites shown in the magnified insets (A’–B’). Bars, 20 µm.
Figure 6: Purification and characterization of the protein-protein interaction between Myo5a tail
and Rab3A.
A, Myo5a tail and Rab3A were analyzed by SDS-PAGE gel electrophoresis stained with Coomassie after
protein purification by affinity and gel filtration chromatography. B-D, Examples of diffusion-free
sedimentation coefficient distributions (c(s)) derived from sedimentation velocity data of individual
Rab3A (2.6 µM, B) and Myo5a tail (0.5 µM, C), and Rab3A plus Myo5a tail together (D). Separate
monomer and dimer peaks were observed in the Myo5a tail sample (C). (D) GTP-bound Rab3A was
found in association with monomeric and dimeric Myo5a tail. The diagrams illustrate possible protein-
protein interactions between Myo5a tail regions and GTP-bound Rab3A. All analytical ultracentrifugation
experiments were performed in the presence of 1 mM GTPγS or 1 mM GDP.
Figure 7: Proposed model for the Myo5a/Rab3A interaction on SVs.
This model integrates the SV abundant membrane proteins Rab3A and Rabphilin3A and illustrates a
possible interaction of the Myo5a tail-domain with the SV. A, The active or GTP-bound form of Rab3A
builds a complex with Rabphilin3A on the surface of SV that binds directly to the globular tail domain of
Myo5a. B, Rab3A dissociates from Myo5a tail and Rabphilin3A after GTP hydrolysis (1) and binds to
















Table 1: Summary of sedimentation coefficients derived from sedimentation velocity analysis of
individual Rab3A and Myo5a tail and the Rab3A/Myo5a tail complex
S* Experimental sedimentation coefficient determined at 10°C (± S.E. from two or three independent
experiments).
S20,W Standard sedimentation coefficient after correcting for water at 20°C.
f/f0 ratio of the experimental frictional coefficient to the theoretical frictional coefficient for a perfect
sphere of the same molecular mass.




Rab3A + 1 mM GTPγS 1.9 ± 0.3 2.1 1.4 23.5 24.9
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